Compiled: Anavex Partnerships
08/08/19 ________________________________________________________________________________________________________________
INDUSTRY CONSORTIUM FOR ERP BIOMARKERS LAUNCHED: Benefit of the Consortium: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150172628 "Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects" - Consortium sponsors.
https://clinicaltrials.gov/ct2/show/NCT04025502 Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147665488 About
erpbiomarkers.org: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147668300 Purpose of the above: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150169319 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150169571 Antipsychotics, also known as neuroleptics, are a class of drugs used to treat psychiatric disorders.. (from kevli33 )
https://youtu.be/nKkIh1B2Js8 Schizophrenia trial Announced: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150013370 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150015845 Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147665488 Daniel C. Javitt, MD | Columbia University Department of Psychiatry https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147699581 Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches.
(link from georgejjl)
https://www.ncbi.nlm.nih.gov/pubmed/28890198 see also:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461562/ Larry Ereshefsky has been working on Schizophrenia for a long time:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147697607 ERP - Cognision and Anavex partnership https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147665488 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147690818 Cognision 510K Certification: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147839850 Notes on the above from TempePhil: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147788179 2015 mention of ERP results at five weeks: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148130307 Biostockclub holds forth on the Consortium and the history of Big Pharma: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147996854 Lima4918- opinions about the Alzheimer's Consortium: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149153359 see also NeuroNetrix below:
________________________________________________________________________________________________________________
NEURONETRIX: Neuonetrix partnership
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166429 Anavex CHOSE Neuronetrix for its A2-73 P2a trial for Alzh. (see Nov. 7,2014 press release).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150174092 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166593 Why does Marco Cecchi (CSO of Neuronetrix) show up as the inventor in this world patent application for 2-73?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147174749 Origins of 3-71:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148063609 ________________________________________________________________________________________________________________
ARIANA: Ariana background info from Kevli 33 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147023718 Corrected link from above: https://www.anavex.com/anavex-life-sciences-and-ariana-pharma-collaborate-to-accelerate-timelines-and-improve-efficiency-of-alzheimers-and-parkinsons-clinical-development-programs/ chi
Anavex and
Ariana (thanks TTAV66)
"Ariana Pharma promoting their work with Anavex. Nice write up, including the further reading section where they point to the upcoming CTAD presentation and detail their full history of collaboration with Anavex. "
http://www.arianapharma.com/2018/09/alzheimer-precision-medicine/ Another article by Ariana Pharma on their website, this time
highlighting the CTAD presentation: http://www.arianapharma.com/2018/10/arianas-ai-demonstrate-clinical-efficacy-of-anavex2-73-for-alzheimers-patient-ctad-2018/ ________________________________________________________________________________________________________________
ALZHEIMER PRECISION MEDICINE INITIATIVE: It’s interesting that Hampel says at the end of this video. “That is why the Alzheimer Precision Medicine Initiative and Anavex is collaborating on this project.” This was most likely pointed out before but worth a second visit.
And also why Hampel uses WE when discussing the trial. How much collaboration was there?
(comment and repost from Jonjones325 on 7/7/19)
The Alzheimer Precision Medicine Initiative Led by Harald Hampel
https://www.apmiscience.com Cbdpotential on systems and reference to a 2017 paper by Harald Hampel: Quote:
A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149737160 Harald Hampel: “That is why the Alzheimer Precision Medicine Initiative and Anavex is collaborating on this project.”
A former member of the Anavex Scientific Advisory Board and an internationally recognized expert on Alzheimer’s and related neurodegenerative diseases, Dr. Hampel is Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC) in Paris, the leading university in science, technology and medicine in France. The AXA-UPMC Chair is hosted within the highly specialized Institute for Memory and Alzheimer’s Disease (IM2A), a reference center for Alzheimer’s and other neurodegenerative diseases, and affiliated with a leading neuroscience institution, the Brain and Spine Institute (ICM), as well as the Department of Neurology at the Pitié-Salpétrière University Hospital. He has conducted more than 50 clinical trials over the past 20 years and has developed international programs focused on Alzheimer’s therapy, diagnosis and the development of biological and imaging biomarkers, including his current work as AXA-UPMC Chair, which aims to improve early detection at the preclinical ‘silent stage’ before the onset of any clinical signs and symptoms. After a post-doctoral fellowship focused on structural and functional neuroimaging of the healthy aging and Alzheimer’s disease brain at the NIH/NIA Laboratory of Neurosciences in Bethesda, MD, Dr. Hampel became founding director of the Alzheimer Memorial Center and Professor of Psychiatry at the University of Munich. In 2006, he was appointed as a Professor and Chair of Psychiatry at Trinity College, University of Dublin, Ireland. During this time, he was a leading Principal Investigator at the Trinity College Institute of Neuroscience (TCIN). In 2010, Dr. Hampel was appointed as Professor, Chair and Head of Department of Psychiatry and Co-Director of the Brain Imaging Center (BIC) at the University of Frankfurt. Dr. Hampel has published more than 500 peer-reviewed research papers, 80 book chapters and eight books, many in world-leading scientific journals, such as the New England Journal of Medicine, JAMA, The Lancet, The Lancet Neurology, Nature Genetics, Nature Reviews Drug Discovery and Nature Reviews Neurology. He has won numerous awards for his scientific work on healthy and diseased brains as well as biomarker and therapy discovery in Alzheimer’s. Additionally, Dr. Hampel has been a reviewer for leading international scientific journals and funding agencies in the US, Canada and Europe and is Senior Associate Editor of the leading international Alzheimer’s journal Alzheimer’s & Dementia, the journal of the Alzheimer’s Association.
Research Gate intro: Quote:
My objective is to transform Neurology, Psychiatry and Neuroscience embracing Precision Medicine based on Complex Systems Theory using Systems Biology and Neurophysiology, Big Data Science and Biomarker-guided Integrative Disease Modeling (IDA) for improved Detection, Classification and Therapy Development in Neurodegenerative Diseases, such as Alzheimer's disease. Towards this end I have launched the Alzheimer Precision Medicine Initiative (APMI) and the APMI cohort program (APMI-CP). Website Alzheimer Precision Medicine Initiative (APMI): https://www.apmiscience.com/
https://www.researchgate.net/profile/Harald_Hampel Hampel's August 2018 statement on the action of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145787370 HH twitter: https://twitter.com/harald_hampel# https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147429124 Revolution of Alzheimer Precision Neurology: Passageway of Systems Biology and Neurophysiology Harald Hampel primary author, posted by nidan7500
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008221/#!po=0.337838 Harald Hampel tweets this paper (from kevli33):
Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450260/ https://twitter.com/harald_hampel/status/1118495219895476226 Hampel on precision Medicine and Alzheimer's https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148302986 Hampel APMI bio link: https://www.apmiscience.com/working-group-1 Dr. Harald Hampel, MD, PhD, MA, MSc:
Genomic Analysis of ANAVEX 2-73 in Alzheimer Disease Study 10/18, Videos: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148601340 Hampel and precision medicine: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138458647 Eisai names Harald Hampel VP Global Medical Affairs https://www.fiercebiotech.com/biotech/eisai-installs-new-alzheimer-s-clinical-trial-leadership-team More on Eisai's Alzheimer's moves.... (from Talon38)
https://www.fiercebiotech.com/biotech/eisai-installs-new-alzheimer-s-clinical-trial-leadership-team https://www.biospace.com/article/eisai-continues-alzheimer-s-research-adds-2-alzheimer-s-pros-as-execs "Our paper on plasma amyloid beat 40/42 ration predicts cerebral amyloidosis in asymptomatic at risk individuals for AD has been published in Alzheimer's & Dementia"(from kevli33 quoting Harald Hampel tweet)
https://goo.gl/scholar/JZH7Zw _________________________________________________________________________________________
COGNISION and NEURONETRIX: Neuonetrix partnership https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166429 Anavex CHOSE Neuronetrix for its A2-73 P2a trial for Alzh. (see Nov. 7,2014 press release).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150174092 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166593 Why does Marco Cecchi (CSO of Neuronetrix) show up as the inventor in this world patent application for 2-73? https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147174749 4/3/19 - New position paper from FDA on AI. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147990271 Summary of the Cecchi ERP patent application...as paid for by Anavex(applicant).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147788179 Tool suite used in the Cognision patent (thanks Nidan7500):
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext https://www.advancedbrainmonitoring.com/ Link to the patent application https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147781853 New EEG techniques for Alzheimer's and other CNS disease under development, including AI:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145774113 A clinical trial to validate
event-related potential markers of Alzheimer's disease in outpatient settings
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext P300 amplitude recovers to healthy levels over 53 weeks in the P2a and extension
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146074463 Cognision protocol for TBI (from georgejjl)
http://www.cognision.com/wp-content/uploads/2018/09/ERP-for-Diagnosis-and-Prognosis-of-Traumatic-Brain-Injury-9-18.pdf Cognision on diagnostic process, FDA approval: http://www.cognision.com/wp-content/uploads/2017/11/Clinical-Study-FDA-Approval.pdf 2015 mention of
ERP results at five weeks:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148130307 Past posts on
Cognision and Erp: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145755014 Possible approval based on sleep, with ERP/EEG taken as suporting biomarker evidence
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148919365 Cognision and ERP/EEG tracking in trials - is this why trials are adding sites slowly? https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148909354 ________________________________________________________________________________________________________________
McGill University: Canadian University that does a lot of
Anavex preclinical research. https://www.mcgill.ca/neuro/ McGill, Merck and Canada's CDRD join in researh effort 2017 https://www.mcgill.ca/neuro/channels/news/health-science-leaders-join-forces-accelerate-development-treatments-neurological-diseases-267104 ________________________________________________________________________________________________________________
Manufacturing Partners: Theory on Anavex Manufacturing partner.. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148205960 ________________________________________________________________________________________________________________
MAYBE MERCK ????: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149038386 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148209671 Merck Canada funding research on 2-73 and 3-71 and possibility of a combo: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148210694 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148210824 ________________________________________________________________________________________________________________
Lund University: Dr. Angela Cenci-Nilsson and Dr. Veronica Francardo's Lund University: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342353 Dr. M. Angela Cenci Nilsson resulting study from the
2015 research grant for Parkinson's: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148339012 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342120 PROFILE
http://www.academia-net.org/profil/prof-dr-m-angela-cenci-nilsson/1488381 Veronica Francardo https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342376 Francardo May 2018 statement on effect of 2-73 in Parkinson's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134044839
Anavex PR's from the Lund preclinical research on Parkinson's by Cenci-Nilsson and Francardo.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148343391 ________________________________________________________________________________________________________________
Manufacturing Partners & Potential Partners: Theory on Anavex Manufacturing partner.. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148205960 More on Eisai's Alzheimer's moves.... (from Talon38)
https://www.fiercebiotech.com/biotech/eisai-installs-new-alzheimer-s-clinical-trial-leadership-team https://www.biospace.com/article/eisai-continues-alzheimer-s-research-adds-2-alzheimer-s-pros-as-execs